Arch Therapeutics files Chapter 11, expects no shareholder recovery; stalking horse bid from Vivex Biologics

Arch Therapeutics, Inc.

Filed Chapter 11 on April 18, 2025; stalking horse bid by Vivex Biologics for substantially all assets.
Court approved bidding procedures; sale hearing set for June 20, 2025. DIP credit bid up to $900K.
Prepetition secured parties to receive $500K carve-out; anticipated no recovery for shareholders.
Auditor Weinberg resigned May 22, 2025; company non-compliant with SEC filings since Sep 2024 10-K.
Securities moved to OTC Expert Market (ARTHQ); board reduced to two members, single officer.

item 1.03item 2.04item 3.01item 4.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.